Having This Common Respiratory Condition Triples The Risk of Dying, Scientists Warn
While RSV is most often associated with infants—it's the leading cause of hospitalization in babies under six months—it also poses a serious risk to older adults. In fact, RSV can lead to severe complications like pneumonia and chronic respiratory disease in adults over 60, resulting in an estimated 100,000 and 150,000 hospitalizations annually.
🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊
However, doctors may have actually underestimated just how dangerous RSV can be for older adults. New research presented at the 2025 European Society of Clinical Microbiology and Infectious Diseases Global conference shows adults with RSV are 2.7 times more likely to die within a year than people without an RSV infection.
Related: Signs of RSV in Older Adults According to Immunologists
Between 2011 and 2022, researchers examined medical data from 5,289 adults diagnosed with RSV. After comparing their health outcomes to 15,867 people of similar age and stature who were not infected with RSV after one year, they concluded the following.
The most significant difference between the two groups was a much higher risk of death. Based on the findings, adults of any age older than 18 faced a 2.7 higher risk of dying within one year of infection compared to the general population.
People with RSV infection had to deal with more severe health problems over all, with hospitalization rates being more than double those without RSV infection (58% vs 28%). They also demonstrated four times higher admission to the intensive care unit (5.3% vs 1.4%).
The repeated RSV-related hospital visits and complications also resulted in hefty medical bills. Over the year, people with RSV infections spent nearly $23,000 in healthcare costs compared to the estimated $10,000 adults without RSV spent.
Related: Who Actually Needs To Worry About RSV in the Coming Weeks
In one year, people with RSV infection were 3.1 times more likely to experience complications from COPD, and 4.6 times more likely to have complications from asthma.
'Exacerbations of COPD and asthma were the most common adverse clinical outcomes. These pre-existing conditions are already challenging in themselves, and RSV-ARI exacerbates their severity," said Maria João Fonseca, Ph.D., an associate director of Global Real World Evidence and Health Outcomes, Vaccines for the pharmaceutical company GSK and the study's lead author. "Because of this, it's crucial that we pay closer attention to patients with these underlying conditions to prevent further, potentially life-threatening complications.'
'One of the most striking findings from this study was the prolonged and significant impact of RSV-ARI,' Fonseca explains. 'Even after the acute phase, patients continued to experience worse outcomes compared to the general population. This underscores just how serious and enduring the effects of RSV-ARI can be.'
Related:
As for how to protect yourself from RSV? Experts recommend getting vaccinated. (There are currently three FDA-approved RSV vaccines, including GSK's AREXY vaccine.)
The Centers for Disease Control and Prevention currently recommends the RSV vaccine for anyone 75 and older. That said, anyone 60 or older who is considered high risk for complications is advised to get immunized as well. If you're unsure where you fall in terms of risk factors, ask your doctor or general practitioner.
'Vaccination has proven highly effective in preventing severe outcomes from RSV," said Stanislava Bratković, a medical advisor for Vaccines at GSK and one of the study's authors. "Given the significant burden of RSV-ARI highlighted by our study, prioritizing vaccination for vulnerable populations is essential to reduce both health complications and associated costs.'
Up Next:About RSV. Centers for Disease Control and Prevention.
RSV in Older Adults. Centers for Disease Control and Prevention.
Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study. European Society of Clinical Microbiology and Infectious Diseases Global 2025.
Maria João Fonseca, Ph.D., is an associate director of Global Real World Evidence and Health Outcomes, Vaccines for the pharmaceutical company GSK.
Stanislava Bratković is a medical advisor for Vaccines at GSK.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
7 hours ago
- Time Magazine
COVID-19 Is Rising Again. Here's What to Know
As much as we want to put it behind us, COVID-19 isn't going away. Cases are currently rising across the country in a summer surge. The U.S. Centers for Disease Control and Prevention (CDC) reports that cases of COVID-19 are increasing in nine states and likely growing in another 16. The trends are estimates, as the CDC no longer conducts rigorous surveillance of cases based on results from lab tests. Fewer people are also getting tested. But the data do provide a hint of how the disease is changing over time, and new monitoring systems that track viruses in wastewater confirm the rise. The CDC says that the overall level of respiratory diseases in the U.S.— COVID-19, flu, and RSV—remains 'very low,' but that emergency room visits for COVID-19 are on the rise, accounting for 0.5% of emergency room visits in the country as of mid July, compared to 0.3% of cases at the beginning of the summer. While that may seem like a small increase, emergency room visits are a bellwether for disease trends, since they represent cases in which people are sick enough to seek care. 'We are starting to hear about more young kids or older adults showing up in the emergency room with COVID-19,' says Dr. Luis Ostrosky, chief of infectious diseases at UT Health Houston. Texas is one of the states seeing spikes in infections. Here's what experts say you need to know about the current surge in cases. Why are COVID-19 cases increasing in the summer? Unlike most respiratory diseases like the common cold and flu, which generally peak during the winter, COVID-19 tends to spike twice and sometimes three times a year: once in the fall and winter, once in spring, and another time in the summer. While viruses tend to spread more easily when people are gathered indoors during cold weather, the post-winter time periods also coincide with 'travel, vacations, and people congregating and going to events,' says Ostrosky. COVID-19 trends also depend on the emergence and spread of new variants. The latest, including NB.1.8.1, are getting better at spreading among people, which contributes to a bump in cases. Read More: What to Do About Your Red, Itchy Eyes Another factor that could be driving the surge in infections is that fewer people are getting vaccinated, for a number of reasons. U.S. health authorities recently changed COVID-19 vaccine recommendations, continuing to recommend yearly shots for older people and those who have weakened immune systems, but allowing otherwise healthy adults more leeway to decide whether to get vaccinated. Many experts, however, continue to encourage people to get them. 'What I tell my colleagues and patients is that we need to follow the evidence, and the best evidence out there is not controversial,' says Ostrosky. 'Vaccines are safe and very effective in preventing severe disease, hospitalizations, mortality, and Long COVID.' It's important for most people to get vaccinated every year to maintain good protection against severe disease, he says, and for those with weaker immune systems, including the elderly, to get vaccinated twice a year. 'I can't tell you how many times I've heard patients ask, 'Do COVID vaccines still work? Am I still supposed to get them?'' With less focus on the vaccines, education and awareness about them is dropping, he says, and that could fuel upticks in cases. Where is COVID-19 rising? According to the latest CDC estimates, the virus is growing in Arkansas, Illinois, Iowa, Kentucky, North Carolina, Ohio, Pennsylvania, Texas, and Virginia. The agency's models find that there is a 95% chance that the epidemic is growing, which means more states could start to see increases in infections. What is the latest dominant COVID-19 variant? Omicron variants still account for all new infections in the U.S., with NB.1.8.1 responsible for 43% of cases as of the end of June. However, the CDC says the low number of cases reported to the agency means the data may not reflect the latest situation. Will the vaccine protect me from COVID-19? The current version of the vaccine targets a different, older Omicron variant, but it remains effective in protecting against severe disease because the viruses are closely related. 'Not only are they all Omicron, but they are from a specific branching of Omicron that is pretty well conserved over the past year and a half,' says Ostrosky. 'So I have pretty good confidence that the vaccine remains a good match for circulating variants.'
Yahoo
9 hours ago
- Yahoo
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, UK. Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, 'with potential milestone payments of up to $450 million based on development and regulatory achievements'. 'We are excited to join Sanofi', said Emmanuel Hanon, Chief Executive Officer at Vicebio, in a statement. 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realise the potential of our innovative technology." With the acquisition, Sanofi gets Vicebio's early-stage combination vaccine candidate for two respiratory viruses, the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Respiratory infections, affecting millions globally, often appear as cold-like illnesses that could, in severe cases, lead to pneumonia. In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is relatively new for vaccines. It teaches the body how to make a protein that triggers an immune response to protect against a specific virus, instead of using a weakened or inactivated germ to trigger this reaction. With the current deal, Sanofi also gets access to Vicebio's Molecular Clamp technology, which stabilises viral proteins in their native shape, triggering a more effective immune response. This technology is expected to speed up vaccine development and simplify manufacturing and distribution. Related EU pharma chief calls for European Nasdaq to boost biotech innovation Doliprane-maker Sanofi confirms exclusive talks with US firm CD&R 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation," said Jean-François Toussaint, global head of research and development vaccines at Sanofi. The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi's financial guidance for 2025. The pharma giant's share price was down around 0.4% before 11:00 CEST in Paris.
Medscape
9 hours ago
- Medscape
Chronic Conditions Raise Risk for RSV Hospitalizations
TOPLINE: Children with chronic medical conditions (CMCs) had higher rates of respiratory syncytial virus (RSV)-related hospitalization than healthy children during their first two RSV seasons, with a sustained elevated risk in the second year. METHODOLOGY: Researchers conducted a retrospective population-based cohort study to identify children with CMCs who were at a higher risk for RSV-related hospitalizations during their first and second RSV seasons. They enrolled 431,937 children (51.4% boys) born in British Columbia, Canada, between April 2013 and March 2023, with or without a CMC, identified through the provincial health registry. The children were followed up until the day before their third RSV season or April 1, 2024, whichever came early. They compared RSV-related hospitalizations between 25,452 children diagnosed with at least one of 1116 distinct CMCs within their first 2 years of life and those without CMCs. The primary outcome was hospitalization due to RSV-related lower respiratory tract infection. Secondary outcomes included pediatric ICU admissions, hospital length of stay, and use of invasive mechanical ventilation. TAKEAWAY: In the first RSV season, the hospitalization rate per 1000 person-years was 15.9 (95% CI, 14.2-17.6) for children with CMCs and 8.0 (95% CI, 7.7-8.3) for those without CMCs. In the second season, the rate was 7.8 (95% CI, 6.7-8.8) for those with CMCs and 2.2 (95% CI, 2.1-2.3) without CMCs. Children with CMCs had longer hospital and pediatric ICU stays and required mechanical ventilation more frequently during their first two RSV seasons than healthy children. RSV-related hospitalization rates in the second season among children with CMCs involving the respiratory, cardiovascular, or gastrointestinal systems were twofold higher than the overall hospitalization rate in the first season. Moreover, children with Down syndrome or those born at less than 28 weeks of gestation had fivefold higher RSV-related hospitalization rates in the second season than all children in the first season. IN PRACTICE: 'Understanding the regional burden of RSV disease is critical to inform local RSV immunization guidelines. In regions with high IRs [incidence rates], a universal RSV prophylaxis program may be warranted. However, in jurisdictions with a lower burden of disease, targeted programs for children at high risk in their second RSV season may be more cost-effective,' the authors wrote. SOURCE: The study was led by Marina Viñeta Paramo, MBBS, Department of Pediatrics, University of British Columbia in Vancouver, British Columbia, Canada. It was published online on July 8, 2025, in JAMA Network Open. LIMITATIONS: The use of retrospective health administrative data may have introduced biases due to coding variability and misclassification of RSV cases. The analysis did not account for the timing of CMC diagnoses or treatments received. The frequent co-occurrence of extreme prematurity in children with CMCs limited the ability to separate their independent effects. Additionally, the database excluded children not registered for provincial health insurance at birth, potentially omitting vulnerable populations. DISCLOSURES: This study was supported by financial aid to three authors, including funding from the British Columbia Children's Hospital Foundation. Two authors received financial support or a scholar award from Michael Smith Health Research BC. One author received grants from Merck, GlaxoSmithKline, Sanofi Pasteur, Moderna, and Pfizer. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
